Product Update from NovoNordisk
| A manufacturing deviation at NovoNordisk’s Danish facility has led to potential underfilling of vials for NovoSeven©, NovoEight©, and Esperoct© – crucial treatments for hemophilia and other blood disorders. While alternative treatments exist for NovoEight and Esperoct, the NovoSeven shortage could have significant implications due to its unique indications and limited alternatives. Read More |
Source: National Bleeding Disorders Foundation, October 2024